Selank 60mg — Vial Spec, Reconstitution Math & COA
A 60mg mass presentation of lyophilized Selank provides high-throughput laboratories with the material volume required for large-scale in vitro assays, multi-plate receptor binding studies, and extended preclinical research pipelines. This document details the physical chemical properties, precise volumetric reconstitution mathematics, aliquot preservation protocols, and analytical batch validation standards for this high-yield research compound. Researchers can evaluate batch purity, structural specifications, and lot-matched documentation to maintain methodological consistency across experimental trials.
Quick answer
A 60mg mass presentation of lyophilized Selank provides high-throughput laboratories with the material volume required for large-scale in vitro assays, multi-plate receptor binding studies, and extended preclinical research pipelines. This document details the physical chemical properties, precise volumetric reconstitution mathematics, aliquot preservation protocols, and analytical batch validation standards for this high-yield research compound. Researchers can evaluate batch purity, structural specifications, and lot-matched documentation to maintain methodological consistency across experimental trials.
Key takeaways
- In experimental settings requiring high-density dosing matrices or parallel analytical assays, standard low-mass vials can introduce workflow bottlenecks and batch-to-batch reconstitution variability.
- [Selank](/research-peptides/selank) is a synthetic heptapeptide with the primary amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro.
- Accurate volumetric reconstitution of a 60mg lyophilized cake requires precise liquid measurement to achieve targeted milligram-per-milliliter (mg/mL) or microgram-per-microliter (µg/µL) concentrations.
- Repeated freeze-thaw cycles subject synthetic peptides to thermal stress, which accelerates peptide bond cleavage and aggregate formation.
High-Mass Lyophilized Vial Specification and Catalog Availability
In experimental settings requiring high-density dosing matrices or parallel analytical assays, standard low-mass vials can introduce workflow bottlenecks and batch-to-batch reconstitution variability. A single 60mg vial of synthetic Selank delivers a continuous material batch suitable for multi-well cell culture screening, automated liquid handler dispensing, or long-term high-throughput preclinical trials. By reconstituting a single high-mass vial, investigators minimize baseline variance across distinct experimental plates.
It is important for laboratory procurement managers to note that while high-mass configurations such as 60mg are manufactured for institutional high-volume requests, PX1 Research maintains standard off-the-shelf inventory in lower mass formats. Investigators seeking immediate dispatch for standard exploratory protocols can review the Selank 10mg product specification. For researchers conducting large-scale operations requiring specialized fill sizes or custom batch allocations across our full range of all peptides, institutional support is available through our dedicated wholesale lab portal.
Each high-mass vial manufactured within our ISO 17025 accredited and GMP-compliant facilities undergoes rigorous lyophilization parameters. This process yields a highly uniform, cake-like solid optimized for rapid dissolution upon introduction of an appropriate aqueous diluent. All fills are performed under sterile, positive-pressure laminar flow hoods to guarantee zero biological contamination prior to vial sealing.
Physicochemical Profile and Structural Properties of Selank
Selank is a synthetic heptapeptide with the primary amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Structurally, it is derived from the naturally occurring immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), elongated at the C-terminus with a Pro-Gly-Pro tripeptide sequence. This structural modification was engineered to enhance metabolic resistance against endogenous peptidases and extend its terminal half-life in physiological fluid media during preclinical investigation.
The molecular weight of free-base Selank is approximately 751.9 g/mol. Preclinical studies suggest that the addition of the Pro-Gly-Pro domain stabilizes the molecular conformation without altering the fundamental binding affinity of the core tuftsin domain. In vitro assays demonstrate that Selank interacts with the GABAA receptor complex, modulating allosteric binding sites without acting as a direct agonist.
Additionally, in vitro enzymatic assays indicate that Selank inhibits enkephalin-degrading enzymes, specifically neutral endopeptidase (NEP) and carboxypeptidase N. This inhibition slows the enzymatic cleavage of endogenous opioid peptides in neuronal cell cultures. When evaluating this compound within neurochemical and immunological models, maintaining precise concentration gradients is paramount to isolating target receptor kinetics.
Precision Reconstitution Mathematics for 60mg Mass Fills
Accurate volumetric reconstitution of a 60mg lyophilized cake requires precise liquid measurement to achieve targeted milligram-per-milliliter (mg/mL) or microgram-per-microliter (µg/µL) concentrations. Because a 60mg mass represents a substantial peptide volume, researchers must account for displacement volume when calculating final concentrations in automated pipetting routines. Utilizing an accurate reconstitution calculator is recommended prior to diluent administration.
When introducing 1.0 mL of bacteriostatic water or sterile 0.9% sodium chloride solution into a 60mg vial, the resulting nominal concentration is 60.0 mg/mL (60 µg/µL). At this high concentration, the solution exhibits elevated viscosity, which may require careful aspiration speed settings on automated liquid handling workstations to prevent volumetric pipetting errors.
Adding 2.0 mL of diluent to a 60mg vial yields a target concentration of 30.0 mg/mL (30 µg/µL). This concentration balances solution viscosity with manageable volumetric draw sizes for standard microcentrifuge tubes. Alternatively, administering 3.0 mL of diluent produces a concentration of 20.0 mg/mL (20 µg/µL), providing an ideal working stock for serial dilution series across 96-well assay plates. Researchers should verify final volumetric yields after complete cake dissolution.
Aliquot Planning, Dilution Matrices, and Assay Integration
Repeated freeze-thaw cycles subject synthetic peptides to thermal stress, which accelerates peptide bond cleavage and aggregate formation. For a 60mg reconstitution, establishing an organized primary aliquot scheme immediately following initial dissolution is critical for maintaining peptide integrity throughout an experimental timeline.
Once the 60mg mass is fully solubilized, the stock solution should be partitioned into single-use micro-aliquots using sterile, low-protein-binding polypropylene microcentrifuge tubes. For example, dividing a 20 mg/mL solution (reconstituted with 3.0 mL) into thirty 100 µL aliquots yields individual working tubes containing exactly 2.0 mg of working stock. This prevents multiple freeze-thaw events for the master batch.
For downstream in vitro applications, working aliquots can be further diluted into cell culture media, phosphate-buffered saline (PBS), or assay buffers immediately prior to plate inoculation. Researchers working with high-density automated systems should ensure that diluent solvents are fully compatible with plasticware to prevent non-specific adsorption of the hydrophobic regions of the heptapeptide sequence.
Stability, Degradation Dynamics, and Laboratory Storage Protocols
In its lyophilized state, high-purity Selank exhibits robust stability when stored at controlled sub-zero temperatures. Unopened vials stored at -20°C maintain structural integrity for extended periods, while long-term archive storage at -80°C protects the peptide against ambient humidity degradation and thermal degradation.
Upon reconstitution, the fluid peptide becomes susceptible to hydrolytic cleavage and bacterial proliferation if exposed to non-sterile environments. Reconstituted stock solutions using bacteriostatic water containing 0.9% benzyl alcohol should be refrigerated at 2°C to 8°C and utilized within 28 days. If unpreserved sterile saline or pure water is utilized as the diluent, the solution must be used immediately or frozen into single-use aliquots.
Preclinical degradation models indicate that aqueous Selank degrades primarily through deamidation and peptide bond hydrolysis at specific proline junctions when exposed to temperatures exceeding 25°C or pH levels outside the 5.0 to 7.5 range. Exposure to direct ultraviolet light also accelerates oxidative pathways. Laboratory protocols must mandate light-protected glass storage and strict thermal monitoring.
Analytical Quality Assurance: HPLC, MS, and Endotoxin Testing
To ensure reproducible data across preclinical research applications, every production lot of Selank undergoes comprehensive analytical validation. PX1 Research mandates that every batch is subjected to high-performance liquid chromatography (HPLC) and electrospray ionization mass spectrometry (ESI-MS) at an independent ISO 17025 accredited laboratory facility.
Chromatographic purity is established via reverse-phase HPLC (RP-HPLC), ensuring a main peak area integration of greater than 98.0%. This analysis confirms the absence of truncated synthesis sequences, incomplete side-chain deprotection fragments, or oxidation byproducts. High-resolution ESI-MS confirms the exact monoisotopic mass matches the theoretical molecular weight of 751.9 g/mol.
Furthermore, because bacterial endotoxins can confound cell culture viability assays and immunological response measurements, all high-mass vials undergo quantitative Limulus Amebocyte Lysate (LAL) testing. PX1 Research enforces a strict endotoxin threshold of less than 0.05 EU/mg. Principal investigators can review complete lot-specific analytical data directly by accessing our online COA database prior to experimental deployment.
Comparing Synthetic Neuropeptide Variants in Preclinical Models
When designing neurochemical research protocols, investigators frequently compare Selank against other synthetic regulatory peptides to evaluate differential signaling pathways and enzymatic resistance. For instance, Semax is an ACTH(4-10) heptapeptide derivative primarily evaluated for its effects on brain-derived neurotrophic factor (BDNF) expression and melanocortin receptor modulation, whereas Selank acts predominantly through GABAA and enkephalinase systems.
Similarly, modified analogs such as N-Acetyl Selank Amidate incorporate N-terminal acetylation and C-terminal amidation. Preclinical in vitro degradation assays demonstrate that these terminal modifications confer superior resistance against aminopeptidases and carboxypeptidases compared to the native Selank sequence, resulting in altered metabolic half-life profiles in plasma environments.
In non-neurological tissue models, researchers often contrast neuropeptides with systemic regenerative peptides like BPC-157 to differentiate central receptor-mediated responses from local tissue signaling cascades. Understanding these distinct structural and functional parameters enables laboratories to select the exact target molecule required for their specific mechanistic hypothesis. Additional technical comparative data is available within our central research literature index.
Selecting the Optimal Mass Format: 10mg vs 60mg Presentations
Choosing between a standard 10mg presentation and a 60mg high-mass fill depends on the experimental scope, fluid handling capacity, and timeline of the research facility. Small-scale pilot studies, assay validation runs, or short-term exploratory tissue cultures generally benefit from lower mass vials, such as the Selank 10mg format, which minimizes diluent volume and eliminates long-term reconstituted storage requirements.
Conversely, high-volume research institutions, contract research organizations (CROs), and multi-laboratory studies benefit substantially from 60mg mass fills. Reconstituting a single large batch lowers per-assay preparation labor, simplifies stock solution tracking, and ensures absolute batch consistency across hundreds of microplate wells.
When purchasing high-mass configurations, facilities must ensure they possess the necessary equipment—such as ultra-low temperature freezers (-80°C), calibrated multichannel pipettes, and non-binding micro-aliquot tubes—to properly manage the full mass yield without compromising peptide stability over time.
Laboratory Handling Procedures and Reconstitution Protocols
To preserve the structural integrity of synthetic Selank during dissolution, laboratory personnel must strictly adhere to physical handling protocols. The introduction of diluent into a lyophilized vial must be executed with care to prevent shear-stress damage to the peptide backbone.
First, allow the lyophilized vial to equilibrate to room temperature before opening or piercing the septum, as opening cold vials can draw ambient moisture into the vacuum, causing localized degradation. Sanitized rubber septa should be pierced with a sterile needle, and diluent should be introduced slowly along the inner glass wall of the vial, rather than sprayed directly onto the lyophilized cake.
Once the diluent is added, gently swirl the vial in a smooth circular motion until the cake completely dissolves into a clear, colorless solution. High-speed mechanical agitation, rigorous shaking, or high-power vortexing must be strictly avoided, as the resulting air-liquid interface shear forces can induce peptide aggregation and denature secondary molecular structures.
Frequently Asked Questions
What is the exact chemical structure and molecular weight of Selank?
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It has a molecular weight of approximately 751.9 g/mol and is a derivative of the naturally occurring immunomodulatory peptide tuftsin, modified with a C-terminal Pro-Gly-Pro sequence.
How much diluent is required to yield a 30 mg/mL concentration from a 60mg vial?
Reconstituting a 60mg lyophilized vial with exactly 2.0 mL of sterile diluent yields a final concentration of 30.0 mg/mL (or 30 µg/µL).
Does PX1 Research regularly stock 60mg vials of Selank?
PX1 Research maintains standard inventory of Selank in 10mg vial sizes. High-mass presentations such as 60mg are available via institutional custom ordering and bulk procurement options through our wholesale portal.
What diluent should be used for long-term reconstituted storage?
Bacteriostatic water containing 0.9% benzyl alcohol is recommended for reconstituted solution storage at 2°C to 8°C for up to 28 days. For immediate frozen aliquoting, sterile 0.9% sodium chloride or PBS may be utilized.
How does PX1 Research verify batch purity for its peptides?
Every production lot undergoes independent ISO 17025 laboratory testing using RP-HPLC to verify chromatographic purity (>98%) and ESI-MS to confirm precise molecular mass, alongside LAL testing for endotoxin levels.
Why must high-speed vortexing be avoided during peptide reconstitution?
Vortexing creates high shear forces and surface tension at the air-liquid interface, which can disrupt delicate peptide bonds, cause conformational changes, and promote molecular aggregation.
What is the endotoxin threshold applied to PX1 synthetic research peptides?
PX1 Research enforces a strict endotoxin limit of less than 0.05 EU/mg across all synthesized research peptides to prevent biological interference in sensitive cell culture models.
Can reconstituted Selank stock solutions be repeatedly frozen and thawed?
No. Repeated freeze-thaw cycles cause physical stress that degrades peptide chains. Reconstituted master batches should be split into single-use micro-aliquots before freezing.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.